Purple Biotech (PPBT) Non-cash Items (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Non-cash Items of -$2.1 million for Q1 2026, down 65.06% year-over-year from -$6.0 million in Q1 2025, and up 29.12% quarter-over-quarter from -$3.0 million in Q4 2025.
Purple Biotech (PPBT) Non-cash Items (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Non-cash Items for 10 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-cash Items fell 65.06% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$7.3 million (down 1.93% YoY), while the FY2025 annual figure was -$6.5 million, up 35.59% from the prior year.
- Non-cash Items advanced to -$2.1 million in Q1 2026 per PPBT's latest filing, from -$3.0 million in the prior quarter.
- Across five years, Non-cash Items topped out at -$1.0 million in Q4 2024 and bottomed at -$7.0 million in Q1 2022.
- Historically, Non-cash Items has averaged -$3.5 million across 5 years, with a median of -$3.0 million in 2022.
- Annual changes were most pronounced in 2024 — Non-cash Items jumped 83.27% — and 2025, when it sank 192.38%.
- Purple Biotech's Non-cash Items stood at -$5.7 million in 2022, then decreased by 5.71% to -$6.0 million in 2023, then surged by 83.27% to -$1.0 million in 2024, then tumbled by 192.38% to -$3.0 million in 2025, then increased by 29.12% to -$2.1 million in 2026.
- Business Quant data shows PPBT's Non-cash Items at -$2.1 million in Q1 2026, -$3.0 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - |
| 10 | Purple Biotech | 127.07 | 127.07 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.09 Mn |
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | -2.95 Mn |
| Dec 31, 2025 | -2.95 Mn |
| Sep 30, 2025 | -1.11 Mn |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -1.13 Mn |
| Mar 31, 2025 | -1.27 Mn |
| Mar 31, 2025 | -1.27 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | -1.95 Mn |
| Sep 30, 2024 | -1.95 Mn |
| Jun 30, 2024 | -2.92 Mn |
| Jun 30, 2024 | -2.92 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -6.04 Mn |
| Dec 31, 2023 | -6.04 Mn |